Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

This phase 1 dose-escalation study determined the maximum tolerated dose (MTD) of oral pomalidomide (4 dose levels) administered on days 1 to 21 of each 28-day cycle in patients with relapsed and refractory multiple myeloma (RRMM). After four cycles, patients who progressed or had not achieved minim...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Richardson, Paul G., Siegel, David, Baz, Rachid, Kelley, Susan L., Munshi, Nikhil C., Laubach, Jacob, Sullivan, Daniel, Alsina, Melissa, Schlossman, Robert, Ghobrial, Irene M., Doss, Deborah, Loughney, Nora, McBride, Laura, Bilotti, Elizabeth, Anand, Palka, Nardelli, Lisa, Wear, Sandra, Larkins, Gail, Chen, Min, Zaki, Mohamad H., Jacques, Christian, Anderson, Kenneth C.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Hematology 2013
Onderwerpen:
Clinical Trials and Observations
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4123324/
https://ncbi.nlm.nih.gov/pubmed/23243282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-08-450742
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items